Collaborating with Patient Partners to Model Clinical Care Pathways in Major Depressive Disorder: The Benefits of Mixing Evidence and Lived Experience

Mary Bunka (), Shahzad Ghanbarian, Linda Riches, Ginny Landry, Louisa Edwards, Alison M. Hoens and Stirling Bryan
Additional contact information
Mary Bunka: University of British Columbia
Shahzad Ghanbarian: University of British Columbia
Linda Riches: Patient Partner
Ginny Landry: Patient Partner
Louisa Edwards: University of British Columbia
Alison M. Hoens: University of British Columbia
Stirling Bryan: University of British Columbia

PharmacoEconomics, 2022, vol. 40, issue 10, No 4, 977 pages

Abstract: Abstract Background Partnering with patients can enrich the design and development of models of clinical care pathways, yet the practice is not commonplace. Guidelines or “best practices” for patient involvement in modeling are scarce. Objectives In this paper, we outline the steps we took to form an effective partnership with patients to design a robust microsimulation Markov model of major depressive disorder care pathways in British Columbia, Canada, with the aim of encouraging other teams to partner with patients in healthcare modeling endeavors. Methods We describe three unique phases of our collaborative process: uncertainty, mapping, and structured collaboration. We then explore the unique contributions the patient partners made, not only to the model itself, but to our process. Key perspectives are shared from both the modeler and the patient partners in their own words. Results The patient partners made distinct contributions by challenging and verifying modeling assumptions, noting limitations of the model, and suggesting areas for future research. Both the patient partners and the modelers saw great value in the partnership and agreed that the model was strengthened by the diversity of the team. Conclusions We present our learning and key recommendations for future modeling teams in the absence of tested frameworks. We encourage more widespread adoption of patient involvement in modeling and the development of guidelines for such work to increase the democracy of scientific decision making.

Date: 2022
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s40273-022-01175-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:40:y:2022:i:10:d:10.1007_s40273-022-01175-1

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-022-01175-1

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().